Galectin Therapeutics (GALT) Receives Daily Coverage Optimism Score of 0.09
Media coverage about Galectin Therapeutics (NASDAQ:GALT) has been trending somewhat positive on Sunday, Accern Sentiment reports. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Galectin Therapeutics earned a news impact score of 0.09 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.5845291007937 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the media stories that may have effected Accern’s rankings:
- Stock to Watch: Galectin Therapeutics Inc (NASDAQ: GALT) – Alpha Beta Stock (alphabetastock.com)
- Analysts suggested mean rating score of 2.00 for Galectin Therapeutics, Inc. (GALT) – Wall Street Morning (wallstreetmorning.com)
- Galectin Therapeutics Inc (NASDAQ:GALT) Investor Investigation – Digital Journal (digitaljournal.com)
- Galectin Therapeutics, Inc. (GALT) Overcome Concerns on Long-Term Commitments – Stock News Stop (stockmarketstop.com)
- Galectin Therapeutics, Inc., (NASDAQ: GALT) – Technical Indicators under Review – Stock Watch (stocksnewstimes.com)
GALT has been the subject of a number of recent analyst reports. HC Wainwright boosted their target price on Galectin Therapeutics from $3.50 to $6.00 and gave the stock a “buy” rating in a research report on Tuesday, November 28th. Roth Capital initiated coverage on Galectin Therapeutics in a research report on Thursday, October 19th. They issued a “buy” rating and a $8.00 target price for the company. ValuEngine lowered Galectin Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Zacks Investment Research raised shares of Galectin Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price target for the company in a research report on Thursday, November 30th. Finally, Seaport Global Securities reaffirmed a “buy” rating and set a $5.00 price target on shares of Galectin Therapeutics in a research report on Friday, October 6th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $5.55.
Galectin Therapeutics (NASDAQ:GALT) last released its quarterly earnings results on Tuesday, November 7th. The company reported ($0.13) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.02. analysts predict that Galectin Therapeutics will post -0.52 earnings per share for the current year.
Galectin Therapeutics Company Profile
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.